Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic Oncology

Volumn 147, Issue 2, 2017, Pages 402-407

  Martin, Lainie P ^a   Konner, Jason A ^b   Moore, Kathleen N ^c   Seward, Shelly M ^d   Matulonis, Ursula A ^e   Perez, Raymond P ^f   Su, Ying ^g   Berkenblit, Anna ^g   Ruiz Soto, Rodrigo ^g   Birrer, Michael J ^h  

^a FOX CHASE CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g IMMUNOGEN INC   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibody drug conjugate; Biopsy; Clinical trial; Folate receptor alpha; Ovarian cancer

Indexed keywords

FOLATE RECEPTOR 1; MIRVETUXIMAB SORAVTANSINE; ANTIBODY CONJUGATE; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROCORTICOGRAPHY; FALLOPIAN TUBE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; KERATOPATHY; NEEDLE BIOPSY; ORGANIZING PNEUMONIA; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLATE RECEPTOR 1; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 85028349802     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.08.015     Document Type: Article

References (31)

1. Choi, S.W., Mason, J.B., Folate and carcinogenesis: an integrated scheme. J. Nutr. 130 (2000), 129–132.
2. Zhao, R., Diop-Bove, N., Visentin, M., Goldman, I.D., Mechanisms of membrane transport of folates into cells and across epithelia. Annu. Rev. Nutr. 31 (2011), 177–201.
3. Elnakat, H., Ratnam, M., Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56 (2004), 1067–1084.
4. Vergote, I.B., Marth, C., Coleman, R.L., Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 34 (2015), 41–52.
5. Kalli, K.R., Oberg, A.L., Keeney, G.L., Christianson, T.J., Low, P.S., Knutson, K.L., et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108 (2008), 619–626.
6. Toffoli, G., Russo, A., Gallo, A., Cernigoi, C., Miotti, S., Sorio, R., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer 79 (1998), 121–126.
7. Marchetti, C., Palaia, I., Giorgini, M., De Medici, C., Iadarola, R., Vertechy, L., et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco. Targets Ther. 7 (2014), 1223–1236.
8. Ledermann, J.A., Canevari, S., Thigpen, T., Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann. Oncol. 26 (2015), 2034–2043.
9. Assaraf, Y.G., Leamon, C.P., Reddy, J.A., The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist. Updat. 17 (2014), 89–95.
10. Lutz, R.J., Targeting the folate receptor for the treatment of ovarian cancer. Trans. Cancer Res. 4 (2015), 118–126.
11. Vergote, I., Armstrong, D., Scambia, G., Teneriello, M., Sehouli, J., Schweizer, C., et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J. Clin. Oncol. 34 (2016), 2034–2043.
12. Endocyte, Inc., Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis. Avaialble at http//investor.endocyte.com/releasedetail.cfm?releaseid=844838, 2014.
13. Chari, R.V., Miller, M.L., Widdison, W.C., Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53 (2014), 3796–3827.
14. Gunderson, C.C., Moore, K.N., Mirvetuximab soravtansine. FRa-targeting ADC; treatment of epithelial ovarian cancer. Drugs Future 41 (2016), 539–545.
15. Oroudje, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol. Cancer Ther. 9 (2010), 2700–2713.
16. Goldmacher, V.S., Audette, C.A., Guan, Y., Sidhom, E.H., Shah, J.V., Whiteman, K.R., et al. High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. PLoS One, 10, 2015, e0117523.
17. Kovtun, Y.V., Audette, C.A., Ye, Y., Xie, H., Ruberti, M.F., Phinney, S.J., et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66 (2006), 3214–3221.
18. Ab, O., Whiteman, K.R., Bartle, L.M., Sun, X., Singh, R., Tavares, D., et al. IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors. Mol. Cancer Ther. 14 (2015), 1605–1613.
19. Moore, K.N., Borghaei, H., O'Malley, D.M., Jeong, W., Seward, S.M., Bauer, T.M., et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer, 2017, 10.1002/cncr.30736.
20. Moore, K.N., Martin, L.P., O'Malley, D.M., Matulonis, U.A., Konner, J.A., Perez, R.P., et al. Safety and activity of Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol. 35 (2017), 1112–1118.
21. Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247.
22. Konner, J.A., Bell-McGuinn, K.M., Sabbatini, P., Hensley, M.L., Tew, W.P., Pandit-Taskar, N., et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin. Cancer Res. 16 (2010), 5288–5295.
23. Sasaki, Y., Miwa, K., Yamashita, K., Sunakawa, Y., Shimada, K., Ishida, H., et al. A phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors. Investig. New Drugs 33 (2015), 332–340.
24. Lorusso, P.M., Edelman, M.J., Bever, S.L., Forman, K.M., Pilat, M., Quinn, M.F., et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J. Clin. Oncol. 30 (2012), 4011–4016.
25. Naumann, R.W., Coleman, R.L., Burger, R.A., Sausville, E.A., Kutarska, E., S.A. Ghamande SA, et al., PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 31 (2013), 4400–4406.
26. Sega, E.I., Low, P.S., Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 27 (2008), 655–664.
27. Maurer, A.H., Elsinga, P., Fanti, S., Nguyen, B., Oyen, W.J., Weber, W.A., Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J. Nucl. Med. 55 (2014), 701–704.
28. Morris, R.T., Joyrich, R.N., Naumann, R.W., Shah, N.P., Maurer, A.H., Strauss, H.W., et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann. Oncol. 25 (2014), 852–858.
29. Despierre, E., Lambrechts, S., Leunen, K., Berteloot, P., Neven, P., Amant, F., et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol. Oncol. 130 (2013), 192–199.
30. Parslow, A.C., Parakh, S., Lee, F., Gan, H.K., Scott, A.M., Antibody-drug conjugates for cancer therapy. Biomedicine, 4, 2016, 14.
31. Eaton, J.S., Miller, P.E., Mannis, M.J., Murphy, C.J., Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31 (2015), 589–604.